Physicians' Academy for Cardiovascular Education

Less prescription of potent P2Y₁₂i and worse outcomes in women with STEMI versus men

Sex-Specific Differences in Potent P2Y12 Inhibitor Use in British Cardiovascular Intervention Society Registry STEMI Patients

Literature - Burgess SN, Shoaib A, Sharp ASP, et al. - Circ Cardiovasc Interv. 2023 Sep;16(9):e012447. doi: 10.1161/CIRCINTERVENTIONS.122.012447

Introduction and methods


According to current European and American guidelines, patients with STEMI undergoing primary PCI should be treated with a high-potency P2Y₁₂ inhibitor (ticagrelor or prasugrel) in combination with aspirin [1,2]. It is known that women with STEMI have worse outcomes than men [3-10], and that women are less frequently prescribed potent P2Y₁₂ inhibitors than men [6-8,11]. However, the role of prescription differences play in sex-based outcome disparities in STEMI is not well known.

Aim of the study

The study aim was to evaluate sex-based differences in potent P2Y₁₂ inhibitor prescription among STEMI patients treated with primary PCI in order to assess the potential role they play in outcome disparities for women with STEMI.


For this observational study, data from 168,818 STEMI patients treated with primary PCI from 2010 to 2020 were collected from the British Cardiovascular Intervention Society national PCI database. Of these patients, 125,687 (74.45%) were male and 43,131 (25.54%) were female.


The primary endpoint was in-hospital mortality. Additional endpoints included: (1) major adverse CV and cerebrovascular events (MACCE), defined as a composite outcome of in-hospital mortality, in-hospital myocardial reinfarction (including Q-wave and non-Q wave MI), and stroke; and (2) in-hospital major bleeding, defined as a composite outcome of clinical major bleeding requiring blood or platelet transfusions, hemorrhagic stroke, tamponade, retroperitoneal hemorrhage, and access-site complication requiring delayed discharge, intervention, or surgery.

Main results


This large observational study using data on STEMI patients undergoing primary PCI from the UK national PCI database showed that women were less likely to receive a potent P2Y₁₂ inhibitor (prasugrel or ticagrelor), were less likely to be treated using radial access , and had higher rates of in-hospital mortality and major bleeding and MACCE compared with men. The authors believe “[t]his study suggests that both closer adherence to guideline-recommended [potent] P2Y₁₂ inhibitors and more frequent use of radial access for women may help to decrease sex-based outcome disparities for patients with STEMI.”


Show references

Find this article online at Circ Cardiovasc Interv.

Share this page with your colleagues and friends: